Weekly literature reviews, landmark trials, and new developments in cardiac intensive care
The landmark DanGer-SHOCK trial demonstrates significant mortality reduction with Impella CP in STEMI-related cardiogenic shock, but at the cost of increased adverse events.
The ECLS-SHOCK trial challenges the assumption that early VA-ECMO improves outcomes in AMI-related cardiogenic shock.
The updated ISHLT 2024 guidelines bring major changes to transplant candidate evaluation, desensitization protocols, and MCS bridging strategies.
S.K.
The World-Class Cardiac Intensivist